Compare Monolithic Power Systems Inc (MPWR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Sana Biotechnology Inc — how do they compare? Monolithic Power Systems Inc trades at $1,190 (market cap $59.16B), while Sana Biotechnology Inc trades at $3.19 (market cap $947.48M). The key difference: Monolithic Power Systems Inc is far larger — about 62.4× Sana Biotechnology Inc's market cap, and Monolithic Power Systems Inc pays a 0.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MPWR | SANA | |
|---|---|---|
Market Cap | $59.16B | $947.48M |
Sector | Utilities | Health |
52-Week High | $1.69K | $5.92 |
52-Week Low | $834.14 | $2.68 |
Enterprise Value | $57.76B | $860.73M |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,218.50, down 0.44% on the day, with a bearish technical signal from moving averages but oversold RSI hints at potential rebound. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $6.50 versus $5.87 expected, and revenue growth projected to rise from $2.79B in 2025 to $3.3B in 2026. A recent partnership with GlobalFoundries aims to scale high-performance power solutions, supporting long-term growth in AI and server markets.
Outlook remains positive driven by AI infrastructure demand and expanding product portfolio, though high valuation multiples (P/E 73.44) pose risks if growth slows. Analyst consensus is strongly bullish with 88% buy ratings and a $1,860 price target, indicating 53% upside. Key risks include premium valuation sensitivity and potential double-ordering concerns in enterprise data segments.
SANA Biotechnology trades at $3.45, down 10.39% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $244.17 million for 2025, with ROE at -152.87%. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data for type 1 diabetes treatment.
Analyst consensus is strongly bullish with 81.82% buy ratings, but high cash burn and negative earnings pose significant risks. Upside potential hinges on clinical success and future profitability, while downside risks include sustained losses and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
